Active material: Combined preparation
When ATH: M09AB52
CCF: The drug with anti-inflammatory and immunomodulatory effects
ICD-10 codes (testimony): B15, B16, B17.1, B18.1, B18.2, E06, G35, H36.0, i20, I21, I70, I73.1, I79.2, I80, I87.0, I89.0, J01, J15, J20, J32, J42, K73, K86.1, L20.8, L70, M02, M05, M08, M45, N00, N03, N10, N11, N30, N41, N60, N70, T14, T14.1, T14.3, T30, Z29.8, Z51.8
When CSF: 05.03.01
Manufacturer: MUCOS PHARMA GmbH&Co (Germany)
◊ Pills, enteric coated red-orange color, round, lenticular, with smooth surface, with a characteristic odor; permitted variations in the color intensity of the outer shell from red-orange to red color.
| 1 tab. | |
| pancreatin | 345 Prot.U.Ph.Eur. |
| papain | 90 FIP UNITS |
| rutozid | 50 mg |
| Bromelain | 225 FIP UNITS |
| trypsin | 360 FIP UNITS |
| lipase | 34 FIP UNITS |
| amylase | 50 FIP UNITS |
| ximotripsin | 300 FIP UNITS |
Excipients: lactose, corn starch, magnesium stearate, stearic acid, Purified water, colloidal silicon dioxide, talc, sucrose.
The composition of the shell tablets: sucrose, talc, a copolymer of methacrylic acid and methylmethacrylate, shellac, Titanium dioxide, White clay, dye yellow-orange (E110), Ponceau 4R dye (E124), povidone, macrogol 6000, triэtiltsitrat, vanillin, Wax Bleached, carnauba wax.
20 PC. – блистеры (2) – пачки картонные.
20 PC. – блистеры (10) – пачки картонные.
800 PC. – флаконы из полиэтилена высокой плотности.
Combined preparation. It is a combination of highly active enzymes of plant and animal origin. Provides immunomodulatory, anti-inflammatory, fibrinolytic, decongestant, antiplatelet and secondary analgesic effect.
Wobenzym has a positive impact on the course of the inflammatory process, It limits the pathological manifestations of autoimmune and immunocomplex processes, a positive effect on performance immunological reactivity. It stimulates and regulates the functional activity of monocytes, macrophages,, natural killer, stimulate anti-tumor immunity, Cytotoxic T lymphocytes, phagocytic activity of cells.
Under the influence of Wobenzym decreases the amount of circulating immune complexes and excretion occurs membrane deposits of immune complexes of fabrics.
Wobenzym reduces the interstitial infiltration of plasma cells. Increases elimination of protein detritus and fibrin deposits in the area of inflammation, It accelerates lysis of toxic products of metabolism and dying tissue, improves the resorption of hematomas and swelling, normalizes permeability of vessel walls.
Wobenzym reduces the concentration of thromboxane and platelet aggregation. Adjusts the adhesion of blood cells, enhances the ability of red blood cells change shape, adjusting their plasticity, normalizes the number of normal discocytes (Platelet) and reduces the total number of activated platelets forms, normalizes blood viscosity, reduces the total number of mikroagregantov, thereby improving microcirculation and blood rheology, as well as the supply of tissues with oxygen and nutrients.
Wobenzym normalize lipid metabolism, reduces the synthesis of endogenous cholesterol, increases the concentration of HDL, reduces atherogenic lipids, improves absorption of polyunsaturated fatty acids.
Wobenzym increases the effectiveness of antibiotic therapy, increasing the concentration of antibiotics in the blood plasma, and the focus of inflammation, and reduces the side effects of antibiotics (dysbiosis).
Wobenzym reduces the severity of side effects, associated with hormonal drugs (incl. hypercoagulability).
Wobenzym regulatory mechanisms of nonspecific protection (production of interferon), thereby demonstrating antiviral and antimicrobial effect.
Upon receiving Wobenzym inside a part of the enzyme preparation are absorbed from the small intestine by resorption of intact molecules and, binding to transport proteins of blood, enter the bloodstream. Then enzymes, migrating on the vascular bed, It accumulates in the area of pathological process.
In the combined therapy:
Prevention:
Wobenzym is recommended for prevention of infectious complications and improve quality of life during chemotherapy- or radiotherapy; viral infections and their complications.
Establish individually, depending on the severity of the disease.
Adults depending on the activity and severity of disease are administered in a dose of 3 to 10 tab. 3 times / day. First 3 day dosing recommended dose is 3 tab. 3 times / day.
At average disease activity the drug is prescribed in a dose 5-7 tab. 3 times / day for 2 weeks. Subsequently, the dose should be reduced to 3-5 tab. 3 times / day. Course - 2 of the week.
At high disease activity the drug is prescribed in a dose 7-10 tab. 3 times / day for 2-3 weeks. Subsequently, the dose should be reduced to 5 tab. 3 times / day. Course - 2-3 Months.
At chronic diseases of long flowing Wobenzym can be used for indications of courses 3 to 6 months or more.
FROM to improve the efficacy of antibiotics and preventing dysbiosis Wobenzym should be used throughout the course of antibiotic therapy at a dose of 5 tab. 3 times / day. After the cessation of antibiotic therapy to restore the intestinal flora should be appointed by Wobenzym 3 tab. 3 times / day for 2 weeks.
During the radiotherapy and chemotherapy Wobenzym should be applied at a dose of 5 tab. 3 times / day until the completion of a course of radiotherapy and chemotherapy in order to prevent infection, improve basic treatment tolerability and quality of life.
FROM prophylactically Wobenzym appointed 3 tab. 3 times / day for 1.5 months with repetition rate 2-3 per year.
For children 5-12 years administered in a daily dose rate of 1 tab. on 6 kg body weight. Children over 12 years the drug is prescribed under the scheme, intended for adults. The duration of treatment is determined individually.
The drug should be taken at least 30 minutes before eating, without chewing, drinking water (200 ml).
Voʙenzim, usually, well tolerated by patients. In most cases, side effects, withdrawal, habituation was not observed even after prolonged use at high doses.
In some cases,: minor changes the consistency and smell of feces, hives (tested at lower doses or discontinuation of therapy).
The patient should be warned, that the appearance of other adverse reactions should be repealed taking the drug and seek medical advice.
With caution and under medical supervision should be given Wobenzym during pregnancy and lactation.
It should be taken into account, that at the beginning of treatment Wobenzym may increase symptoms. In such cases it is advisable to temporarily reduce the dose, Treatment should not be interrupted.
When infectious and inflammatory diseases Wobenzym does not replace antibiotic treatment, but increases their efficiency.
Wobenzym is not a doping.
Effects on ability to drive vehicles and management mechanisms
The drug has no negative impact on the ability to drive a car and perform work, requiring a high rate of psychomotor reactions.
No cases of overdose were reported Wobenzym.
When concomitantly Wobenzym with other drugs known incompatibilities.
The drug is resolved to application as an agent Valium holidays.
List B. The drug should be stored out of reach of children, dry place with a temperature of 15 ° to 25 ° C. Shelf life - 2.5 year.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More